Get the Stockscreener App
3.15
1.25%
-0.04
After Hours:
3.16
0.01
+0.32%
Atea Pharmaceuticals Inc stock is traded at $3.15, with a volume of 232.78K.
It is down -1.25% in the last 24 hours and down -10.00% over the past month.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
See More
Previous Close:
$3.19
Open:
$3.19
24h Volume:
232.78K
Relative Volume:
0.59
Market Cap:
$246.10M
Revenue:
$351.37M
Net Income/Loss:
$-174.01M
P/E Ratio:
-1.5217
EPS:
-2.07
Net Cash Flow:
$-126.94M
1W Performance:
-0.63%
1M Performance:
-10.00%
6M Performance:
-1.87%
1Y Performance:
+6.78%
1-Day Range:
$3.14
$3.2265
1-Week Range:
$3.105
$3.235
52-Week Range:
$2.455
$4.02
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals Inc
Sector
Industry
Phone
857-204-8109
Address
225 FRANKLIN STREET, BOSTON
Compare AVIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.15 | 249.22M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-25-20 | Initiated | Evercore ISI | Outperform |
| Nov-24-20 | Initiated | JP Morgan | Overweight |
| Nov-24-20 | Initiated | Morgan Stanley | Overweight |
| Nov-24-20 | Initiated | William Blair | Outperform |
View All
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
We're Keeping An Eye On Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Rate - Yahoo Finance
How Atea Pharmaceuticals Inc. stock trades during market volatilityTrade Risk Assessment & Community Verified Trade Signals - Newser
Is Atea Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Macro Moves & Daily Growth Stock Tips - Newser
How Atea Pharmaceuticals Inc. stock valuations compare to rivalsTake Profit & Fast Entry High Yield Tips - Newser
How Atea Pharmaceuticals Inc. stock performs after earningsJuly 2025 Action & AI Enhanced Trading Signals - Newser
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman - Stock Titan
Atea Pharmaceuticals director Franklin Berger acquires $81,498 in stock - MSN
Will Atea Pharmaceuticals Inc. stock beat EPS estimatesTrade Risk Report & Expert Approved Momentum Trade Ideas - newser.com
Is Atea Pharmaceuticals Inc. stock reversal real or fake2025 Winners & Losers & Technical Pattern Based Buy Signals - newser.com
Will Atea Pharmaceuticals Inc. stock outperform growth indexesJuly 2025 Action & Momentum Based Trading Ideas - newser.com
How strong is Atea Pharmaceuticals Inc. stock revenue growth2025 Historical Comparison & Growth Focused Investment Plans - newser.com
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... By GuruFocus - Investing.com Canada
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference - Yahoo Finance
Is a relief rally coming for Atea Pharmaceuticals Inc. holdersProduct Launch & High Return Trade Opportunity Guides - newser.com
How Atea Pharmaceuticals Inc. stock performs in rate cut cyclesQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com
Atea Pharma (AVIR) Earnings Call Transcript - AOL.com
William Blair Has Negative Outlook of AVIR FY2025 Earnings - Defense World
Atea Pharmaceuticals Inc. stock trend outlook and recovery pathMarket Growth Report & Reliable Price Action Trade Plans - newser.com
Live market analysis of Atea Pharmaceuticals Inc.CEO Change & AI Enhanced Market Trend Forecasts - newser.com
Backtesting results for Atea Pharmaceuticals Inc. trading strategiesJuly 2025 Summary & Real-Time Market Sentiment Reports - newser.com
Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism - MSN
Key metrics from Atea Pharmaceuticals Inc.’s quarterly dataMarket Trend Report & Fast Moving Stock Trade Plans - newser.com
What Makes HDFC Mutual fund a Strong Contender in YEAREarnings Call Summaries & Fast Growing Portfolio - earlytimes.in
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2025 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:AVIR) 2025-11-14 - Seeking Alpha
Atea Pharmaceuticals Advances Antiviral Programs with New Data - TipRanks
Atea Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Atea Pharmaceuticals Q3 2025 sees EPS miss By Investing.com - Investing.com Nigeria
Atea Pharmaceuticals Inc Stock (AVIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):